<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818476</url>
  </required_header>
  <id_info>
    <org_study_id>x</org_study_id>
    <nct_id>NCT04818476</nct_id>
  </id_info>
  <brief_title>Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus</brief_title>
  <official_title>Outcomes of Endoscopically Resected High-risk Mucosal Adenocarcinoma and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus: an International Multicenter Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess lymph node metastasis rate, distant metastasis rate,&#xD;
      disease-specific mortality, and overall mortality in patients with Barrett's related T1b and&#xD;
      high risk T1a esophageal adenocarcinoma (EAC) who underwent a diagnostic endoscopic&#xD;
      resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of esophageal adenocarcinoma (EAC) has increased six-fold over the last three&#xD;
      decades, making it the most rapidly rising cancer in the Western world. The main histologic&#xD;
      risk factor for development of EAC is the presence of Barrett's esophagus (BE). BE can&#xD;
      develop from non-dysplastic BE, to low (LGD) and high grade dysplasia (HGD) and, eventually,&#xD;
      EAC.&#xD;
&#xD;
      The past two decades minimally invasive endoscopic resection (ER) has replaced surgical&#xD;
      esophagectomy as first-choice therapy for the treatment of early neoplastic lesions in&#xD;
      Barrett's esophagus. ER provides adequate tissue specimens, allowing for accurate&#xD;
      histopathological staging of a lesion, by assessment of invasion depth, differentiation&#xD;
      grade, presence of lympho-vascular invasion (LVI), and radicality of the resection.&#xD;
      Endoscopic resection thus similarly fulfils a diagnostic and therapeutic role in the&#xD;
      management of Barrett's neoplasia.&#xD;
&#xD;
      However, ER offers local treatment and does not include lymph node dissection as is still&#xD;
      standard of care during esophagectomy. Therefore, the choice to perform endoscopic follow-up&#xD;
      after a radical ER of an early EAC, or to refer a patient for additional surgery, is guided&#xD;
      by the assumed risk of lymph node metastasis (LNM).&#xD;
&#xD;
      Data from previous studies show that the risk of LNM is only 1% in patients with low risk&#xD;
      mucosal EAC after endoscopic treatment (i.e., infiltration depth limited to the mucosa,&#xD;
      G1-G2, without LVI), and &lt;2% in low risk submucosal EAC (i.e., infiltration depth &lt;500μm,&#xD;
      good to moderate differentiation grade (G1-G2), without LVI). In high risk submucosal EAC&#xD;
      (i.e., infiltration depth ≥500 μm, and/or G3-G4, and/or LVI), the LNM risk is estimated to be&#xD;
      much higher (16-44%). Nevertheless, these numbers are mainly based on old surgical series.&#xD;
&#xD;
      Current data is limited in terms of small and heterogeneous patient cohorts, and data for&#xD;
      patients with high risk T1a EAC is not available at all. Therefore, we would like to conduct&#xD;
      an international multicenter retrospective cohort study in &gt;10 centers to evaluate the safety&#xD;
      and efficacy of endoscopic treatment and follow-up of patients with high risk mucosal and&#xD;
      submucosal EAC. Our main focus will be the presence of lymph node metastasis and EAC related&#xD;
      death.&#xD;
&#xD;
      Aim of this registration study is to collect data of the above-mentioned group of patients&#xD;
      and thereby assess lymph node metastasis rate, disease-specific mortality, and overall&#xD;
      mortality.&#xD;
&#xD;
      This study will be conducted according to the principles of the Declaration of Helsinki and&#xD;
      in accordance with the Medical Research Involving Human Subjects Act (WMO), the Medical&#xD;
      Treatment Contracts Act (WGBO) and the Dutch Personal Data Protection Act (WBP). The&#xD;
      investigators will perform the study in accordance with this protocol and will make sure that&#xD;
      participants do not object to using their data. Collection, recording, and reporting of data&#xD;
      will be accurate and will ensure the privacy, health, and welfare of research subjects during&#xD;
      and after the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>lymph node metastasis rate</measure>
    <time_frame>10 years</time_frame>
    <description>Confirmed by cytology and/or histology by performing FNA during EUS or biopsies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>distant metastasis rate</measure>
    <time_frame>10 years</time_frame>
    <description>Primary tumor of distant metastasis should be histopathologically evalueted by taking biopsies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disease-specific mortality</measure>
    <time_frame>10 years</time_frame>
    <description>Disease specific mortality is decribed as mortality directly linked to the esophageal adenocarcinoma (i.e., metastasized EAC, metastasized disease with a simultaneously primary cancer present and it cannot be ruled out (based on histology) that the metastases are related to the other primary cancer, death due to complications of the endoscopic procedure, death due to complications after surgery or CRT, no clear cause of death in patients who have metastases or untreated local recurrence). If patients are diagnosed with distant metastases, and subsequently die of a non-tumor related cause, patients will still be documented as tumor-related death. Will be measured in number of patients and percentages. Survival analysis using Kaplan Meier will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall mortality</measure>
    <time_frame>10 years</time_frame>
    <description>Overall mortality of study population (tumor-related + non-tumor-related deaths). Measured in numbers and percentages, survival analysis (KM).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Adenocarcinoma Esophagus</condition>
  <condition>Submucosal Esophageal Adenocarcinoma</condition>
  <condition>High-risk Mucosal Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>HR-T1a</arm_group_label>
    <description>Patients who weretreated by radical endoscopic resection for a high-risk mucosal EAC (HR-T1a N0M0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LR-T1b</arm_group_label>
    <description>Patients who were treated by radical endoscopic resection for a low-risk submucosal EAC (LR-T1b N0M0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HR-T1b</arm_group_label>
    <description>Patients who were treated by radical endoscopic resection for a high-risk submucosal EAC (HR-T1b N0M0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic endoscopic resection</intervention_name>
    <description>diagnostic endoscopic resection</description>
    <arm_group_label>HR-T1a</arm_group_label>
    <arm_group_label>HR-T1b</arm_group_label>
    <arm_group_label>LR-T1b</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent a diagnostic ER for Barrett's related HR T1a or T1b EAC in one of&#xD;
        the participating centers, from 1/1/2008 up to the moment of data collection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, all ages&#xD;
&#xD;
          2. Endoscopic resection of a histologically proven high risk T1a, low risk T1b EAC, or&#xD;
             high risk T1b EAC&#xD;
&#xD;
          3. Between 1/1/2008 and 1/1/2019&#xD;
&#xD;
          4. Endoscopic resection and endoscopic FU (or other treatment after ER) have taken place&#xD;
             in the participating center&#xD;
&#xD;
          5. No written or oral refusal to use subject's data&#xD;
&#xD;
        Exclusion Criterium:&#xD;
&#xD;
        Objection against participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R.E. Pouw, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Man Wai Chan, MD</last_name>
    <phone>(0)20 4442432</phone>
    <email>m.w.chan@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wilda Rosmolen, MSc</last_name>
    <phone>(0)20 4442432</phone>
    <email>w.d.rosmolen@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westmead hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Bourke, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Bisschops, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Coron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H. Messmann</last_name>
      <email>Helmut.Messmann@uk-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EVK Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horst Neuhaus</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MRI TUM</name>
      <address>
        <city>Münich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Schlag</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barmherzige Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Pech</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Haga Medical Center</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hirslanden private hospital group</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Seewald</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. Haidry, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>R. Haidry, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>prof. dr. J.J.G.H.M. Bergman</investigator_full_name>
    <investigator_title>Professor of Gastrointestinal Endoscopy</investigator_title>
  </responsible_party>
  <keyword>Barrett Esophagus</keyword>
  <keyword>Submucosal esophageal adenocarcinoma</keyword>
  <keyword>Endoscopic treatment</keyword>
  <keyword>Endoscopic follow-up</keyword>
  <keyword>High-risk mucosal esophageal adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

